Sumatriptan drug data and news

---

Pain Therapeutics - Drugs, Markets and Companies  16 May 2006
Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan. ... - PharmaLive.com (press release),

Aradigm Reports First Quarter 2006 Financial Results and Corporate ...  May 15, 2006
...period obligations, the pay-down of accounts payable for the fourth quarter of 2005 activities tied to completion of the Intraject Sumatriptan stability lot ... - Market Wire (press release)

Spectrum Pharmaceuticals Reports First Quarter 2006 Financial ...  May 8, 2006
...into a strategic alliance with Par Pharmaceuticals to distribute our generic products, including, once approved by the FDA, sumatriptan succinate injection ... - PR Newswire (press release),

Your health questions answered  May 2, 2006
One, sumatriptan nasal spray, can be used once a child is 12. Until then, I suggest trying ibuprofen at the first sign of headache. ... - Independent,

Experts recommend Aspirin® for the treatment of migraine  Apr 27, 2006
...“Studies have confirmed that ASA is as effective in the treatment of migraine attacks as the prescription drug sumatriptan,� said Professor Hans-Christoph ... - WebWire (press release),

No More Headaches?  Apr 17, 2006
But it spent less than $30 million on the development of Trexima, which is a combination of sumatriptan, the active ingredient in Imitrex, and the anti ... - Forbes

Ask the Clinician: Answers to Readers' Questions  May 8, 2006
Treatment has been from ergotamine to sumatriptan, Botox to PFO closure, aspirin to Methysergide, homoeopathy to acupuncture to osteopathy, feverfew to lavender ... - About - News & Issues,

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.

MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated .

Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.